Last updated: May 28, 2026
Fluphenazine decanoate is a first-generation (typical) antipsychotic supplied through a small set of established commodity API manufacturers and multiple finished-dose labelers. Supply risk is concentrated in API availability, depot sterile manufacturing capacity, and regulatory-held alternate-site controls for the injectable (IM) presentation.
Who supplies the fluphenazine decanoate active pharmaceutical ingredient (API)?
What API suppliers provide fluphenazine decanoate for injectable manufacturing?
Fluphenazine decanoate is typically sourced as:
- Fluphenazine decanoate API (used for sterile injectable dosage forms).
- In some cases via third-party API-to-drug substance conversion from upstream chemical intermediates.
Supplier qualification in the US is generally done through CMC packages aligned to DMFs/ASMFs tied to approved ANDAs and manufacturing change control histories. Finished-dose manufacturers then lock long-term supply for the IM formulation because sourcing variability can trigger regulatory amendments tied to particle properties, oil phase compatibility, and viscosity specifications.
Which supplier categories dominate?
- API DMF/ASMF holders supplying fluphenazine decanoate for generics and authorized generics.
- Contract sterile injectables manufacturers that fill and finish fluphenazine decanoate for multiple labelers under shared sterile fill-finish lines.
- Finished-dose brand and generic labelers that manage depot injectable release testing and distribution.
Who manufactures and labels fluphenazine decanoate injection (IM)?
Which companies sell fluphenazine decanoate injection in the US?
Finished-dose product availability is driven by multiple generic labelers. In practice, the market is characterized by:
- Multiple NDC holders with similar strengths and packaging.
- Shared contract manufacturing relationships across labelers for sterile filling and packaging.
- Regulatory submissions that keep formulation and manufacturing controls consistent across sites to preserve approval status.
What dosage forms are most commonly supplied?
- Injection (IM depot) (typically supplied as an oily solution/suspension depending on the specific product specification).
- Strengths vary by labeler and NDC configuration, but depot IM offerings remain the focus.
How does supplier structure affect regulatory and quality continuity?
What manufacturing steps create the biggest supplier bottlenecks?
For fluphenazine decanoate IM injectables, the highest-friction areas for supplier continuity are:
- Sterile fill-finish capability for depot injectables (aseptic processing, holding times, and validated filtration or sterilization approach consistent with product specifications).
- Container-closure system controls (oil compatibility, rubber stopper extractables, and leachables).
- Physical specification control (viscosity, droplet/particle distribution if applicable, and uniformity).
- Stability under depot storage conditions (temperature excursions and shelf-life stability program adherence).
Do labelers rely on contract sterile manufacturing?
Yes. Many injectable generics are manufactured through CDMOs where the labeler owns the submission and release specifications while the CDMO owns batch execution, sterile compounding, filling, and packaging under an agreed quality system.
Which procurement and compliance issues matter for fluphenazine decanoate suppliers?
What documentation typically governs supplier qualification?
Procurement of API and sterile injectables is usually anchored in:
- DMF/ASMF alignment for API source and manufacturing route.
- Quality agreements covering specification, change notifications, deviation handling, and batch release.
- Stability and analytical method transfer expectations for scale changes.
What change types can trigger regulatory work?
- API site changes or route changes (new polymorph/impurity profile risks).
- Sterile fill-finish site change or equipment change impacting critical process parameters.
- Container-closure substitute or change in supplier of key components (stopper, vial, crimp caps, labels).
- Solvent/vehicle or excipient sourcing changes affecting oil phase compatibility and viscosity.
What is the supplier landscape for fluphenazine decanoate compared with other depot antipsychotics?
How does the fluphenazine decanoate supply chain compare with fluphenazine enanthate?
Both are depot fluphenazine formulations with similar clinical use and depot injection supply constraints. Supplier differentiation is usually driven by:
- Whether sterile fill-finish capacity is already validated for one depot oil formulation and container configuration.
- Whether API suppliers provide both ester forms with shared intermediates and shared impurity control strategy.
Depot injectable supply is generally more constrained than oral generics due to sterile manufacturing throughput and validated aseptic processes.
Key Takeaways
- Fluphenazine decanoate supply is concentrated in a limited number of qualified API sources and a smaller set of sterile injectables manufacturing networks.
- Bottlenecks for continuity are sterile fill-finish capacity, depot-specific physical specifications, and container-closure compatibility.
- Supplier selection is typically governed by DMF/ASMF-aligned API control and validated sterile manufacturing execution under a quality agreement with the labeler.
FAQs
1) Which DMF/ASMF holders supply fluphenazine decanoate API for US generics?
The answer depends on the specific ANDA/holder and the FDA filing that lists the API source. Supplier identification is tied to the specific regulatory application and listed manufacturing sites.
2) Are there contract manufacturing relationships for fluphenazine decanoate injections?
Yes. Finished-dose labelers often use contract sterile fill-finish providers for depot injectable manufacturing and packaging.
3) What excipients and container systems drive formulation risk in fluphenazine decanoate?
Depot oil phase compatibility, stopper extractables/leachables, and viscosity/dispersion specifications are the key formulation controls.
4) What triggers supply disruptions most often for depot injectables like fluphenazine decanoate?
API availability and sterile fill-finish throughput or site compliance events are the most common disruption drivers.
5) How can a buyer reduce fluphenazine decanoate supply risk?
Qualification diversification across multiple qualified finished-dose labelers or pre-qualified contract manufacturers, with defined change-control pathways, reduces single-source exposure.
References
- FDA. Drugs@FDA database. U.S. Food and Drug Administration. (Accessed 2026-05-29).
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026-05-29).
